Barrow Hanley Mewhinney & Strauss LLC Boosts UnitedHealth Group Holdings

Investment firm increases stake in healthcare conglomerate by 0.4% in Q3 2025

Mar. 11, 2026 at 7:33am

Barrow Hanley Mewhinney & Strauss LLC, an investment management firm, raised its position in UnitedHealth Group Incorporated (NYSE:UNH) by 0.4% during the third quarter of 2025, according to the company's latest Form 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 1,006,676 shares of the healthcare conglomerate's stock, valued at approximately $347.6 million.

Why it matters

UnitedHealth Group is one of the largest healthcare companies in the United States, providing a wide range of insurance and healthcare services. The increase in Barrow Hanley Mewhinney & Strauss LLC's stake in the company suggests the investment firm's confidence in UnitedHealth Group's long-term growth potential.

The details

Barrow Hanley Mewhinney & Strauss LLC, a Dallas-based investment management firm, added 4,053 shares of UnitedHealth Group to its portfolio during the third quarter of 2025. This increased the firm's total holdings in the company to 1,006,676 shares, representing approximately 0.11% of UnitedHealth Group's outstanding shares.

  • Barrow Hanley Mewhinney & Strauss LLC filed its 13F report for the third quarter of 2025 on March 11, 2026.

The players

Barrow Hanley Mewhinney & Strauss LLC

An investment management firm based in Dallas, Texas that manages a variety of investment strategies, including value-oriented equity and fixed income portfolios.

UnitedHealth Group Incorporated

A diversified healthcare company headquartered in Minnetonka, Minnesota that provides a broad range of health benefits and healthcare services to individuals, employers, governmental entities, and other organizations.

Got photos? Submit your photos here. ›

The takeaway

The increase in Barrow Hanley Mewhinney & Strauss LLC's stake in UnitedHealth Group suggests the investment firm's confidence in the healthcare conglomerate's long-term growth potential, as it continues to be a dominant player in the U.S. healthcare industry.